Evidence guide · UAE
DSIP, the "deep sleep peptide": what the evidence shows and why FDA advisers voted no
DSIP is sold as a deep-sleep peptide. Its insomnia trials date from the 1980s and disagree, and in July 2026 FDA advisers voted against recommending it for pharmacy compounding. What the evidence and the risks are.
Review type: research summary. This page summarises published research and product labels, cited below.
DSIP, short for delta sleep-inducing peptide and given the official name emideltide, is a nine-amino-acid peptide sold as injections and nasal sprays for deeper sleep. It was isolated in 1977 by a group in Basel from the cerebral venous blood of rabbits, and was studied in people with insomnia in the 1980s. It is back in the news because it was the one peptide that missed out. At a US Food and Drug Administration (FDA) advisory committee meeting on 24 July 2026, members voted 7 to 6, with one abstention, against adding emideltide to the list of substances that pharmacies may use for compounding. When the US Department of Health and Human Services (HHS) published its interim peptide policy in the Federal Register on 30 October 2026, it covered six other peptides and left emideltide out.
Short answer: the human evidence is small, old and contradictory. The positive trials come mostly from one research group, and two double-blind trials from other teams found little clinically meaningful benefit, and the FDA concluded that the evidence for intravenous use in chronic insomnia is inconclusive and at best preliminary, with no studies at all of the under-the-skin injections now being sold. FDA also says the data it reviewed do not establish the identity, purity or impurity profile of the substance. Skip DSIP and take persistent insomnia to a doctor.
What DSIP is supposed to do
The name comes from the delta waves seen on brain recordings during deep, slow-wave sleep. Despite the name, its role in sleep has never been settled. A 2006 review in the Journal of Neurochemistry, titled "a still unresolved riddle", says the link between DSIP and sleep has never been further characterised, partly because the DSIP gene, protein and possible related receptor have not been isolated, and calls the hypothesis that DSIP is a sleep factor extremely poorly documented and still weak. The same review notes that in its authors' early animal studies, some artificial DSIP analogues promoted slow-wave sleep but DSIP itself did not.
What the human trials show
The human studies the FDA reviewed used intravenous injections: across them, doses of 25 to 150 nmol per kg of body weight were given to 209 people for 1 to 15 days. The FDA found no clinical studies of emideltide given under the skin. The trials in chronic insomnia split into two camps.
- Positive reports, mostly from Schneider-Helmert and colleagues: in a 1986 study of 18 people with chronic insomnia given six intravenous doses over a week, the author reported that the whole group showed normal sleep patterns by the end of a one-week follow-up, and in a 1987 double-blind study of 14 middle-aged people with severe chronic insomnia, which the author called placebo-controlled, the author reported substantially improved night sleep and better daytime alertness and performance. The FDA briefing says that study compared people with their own baseline and with healthy people outside the trial, and that it had no placebo arm of people with insomnia.
- Monti and colleagues, 1987: a double-blind crossover trial gave 25 nmol/kg or placebo intravenously over four nights. Awakenings and time awake fell on DSIP, but not significantly compared with baseline or with placebo nights. Total sleep time rose, mainly in light stage 2 sleep, while deep slow-wave sleep and REM sleep did not change. The authors concluded that sleep improvement under DSIP is of little clinical significance.
- Bes and colleagues, 1992: 16 people with chronic insomnia were given 25 nmol/kg DSIP or a glucose placebo intravenously before three nights in a sleep laboratory, in a double-blind design. Sleep efficiency was higher and time to fall asleep shorter with DSIP, but the authors called these effects weak and possibly partly due to an incidental change in the placebo group. Subjective sleep quality did not change. Their conclusion: short-term DSIP is not likely to be of major therapeutic benefit for chronic insomnia.
The FDA's July 2026 briefing document reviewed this literature and concluded that there were no data to support emideltide given by the under-the-skin route proposed for compounding, and insufficient evidence to reach any conclusion on intravenous emideltide for chronic insomnia. It flagged poor or missing control groups, small samples and within-person comparisons, and said it was unclear whether the reported changes were clinically meaningful. For narcolepsy, the agency found one case report from 1984. For opioid withdrawal, it found older studies, including a 1984 study in people withdrawing from alcohol and opiates and a 1998 open trial.
Safety and quality
The FDA searched its adverse event database through 3 March 2024 and found zero reports for emideltide, which reflects how little it has been formally studied or reported, not proof of safety. The intravenous insomnia studies reported no significant adverse events. In the 1984 withdrawal study, the FDA reports that 9 of 107 people had minor, short-lived side effects such as sweating, headache, nausea and vertigo, and three had serious reactions, including two with low blood pressure at the start of the first injection. The FDA says those reactions are hard to separate from alcohol and opiate withdrawal itself.
The agency's main concerns are about what is in the vial. It describes emideltide as not well characterised physically and chemically, with inconsistent naming, no public impurity test results, and missing endotoxin testing for an injectable product. It says a peptide of this length has the potential to trigger an immune response, and that this response may be stronger if the peptide is injected, potentially amplified by aggregation and peptide-related impurities. It also notes that no form of emideltide is a registered medicine in any country it searched or appears in the European, Japanese or International pharmacopoeias. On the FDA page about bulk substances that may present significant safety risks in compounding, emideltide (DSIP) appears under nominations that were withdrawn, not in the current category 2 table. That entry says the agency has not identified safety information for the proposed route and lacks sufficient information to know whether the drug would cause harm if given to people.
The FDA also found US integrative neurology clinics, medical concierge services, medical spas, wellness clinics and online retailers marketing emideltide injections and nasal sprays for uses that included sleep disorders, stress, pain, cancer, neurodegenerative diseases (Alzheimer's disease and Parkinson's disease) and alcohol and drug detoxification, and said many of these websites do not clearly state whether their products are compounded.
Our view
- The evidence is old and thin. The insomnia trials the FDA reviewed date from the 1980s and 1992, and the double-blind trials from outside the original research group found weak or clinically insignificant effects.
- The products on sale do not match the research. The studies used intravenous injections, while the products the FDA found on the market are under-the-skin injections and nasal sprays, and the FDA found no studies of the under-the-skin route.
- Quality is unknown. FDA says it cannot confirm identity, purity or impurity profiles for emideltide, and immune reactions are a specific concern with injected peptides.
- Chronic insomnia has treatments with real evidence. In the American College of Physicians guideline cited by the FDA, cognitive behavioural therapy for insomnia (CBT-I) is the initial treatment it recommends for chronic insomnia in adults.
- If you have already used DSIP, tell your doctor. Stop and get medical advice if you feel unwell, including a reaction where it was injected, a rash, dizziness or faintness. That is a precaution, not a list of effects the trials established.
UAE rules
On 29 July 2026 the Dubai Health Authority issued circular CIR-2026-00000107, "Regulations for Handling Peptide Products in Healthcare Facilities", to all health professionals and facilities under its jurisdiction. A clinic offering peptide injections in Dubai should be DHA-licensed and able to explain how it meets that circular. The FDA found no form of emideltide registered as a drug in any country it searched. For ongoing sleep problems, see a doctor, and ask a pharmacist at Bin Sina, Supercare or Medicina before combining any sleep product with your other medicines.
FAQ
What is DSIP?
Delta sleep-inducing peptide, also called emideltide: a nine-amino-acid peptide first isolated in 1977 and studied for insomnia, narcolepsy and drug withdrawal, mostly in the 1980s.
Does DSIP help you sleep?
There is no reliable evidence that it does. Small intravenous trials gave mixed results, two double-blind trials found weak or clinically insignificant effects, and the FDA called the evidence inconclusive and at best preliminary.
Is DSIP legal?
It is not an approved medicine anywhere the FDA searched. In the US, an FDA advisory committee voted against recommending that it be added to the list pharmacies may compound from, and it is not one of the six peptides in the October 2026 HHS interim policy.
Sources
These are the documents this page relies on.
- FDA briefing document for emideltide-related bulk drug substances (emideltide (free base) and emideltide acetate), Pharmacy Compounding Advisory Committee meeting, 23-24 July 2026US Food and Drug Administration
- FDA presentations, Pharmacy Compounding Advisory Committee meeting, 24 July 2026US Food and Drug Administration
- July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory CommitteeUS Food and Drug Administration
- FDA panel votes to exclude peptide emideltide from pharmacy compounding list, 24 July 2026Reuters
- Certain bulk drug substances for use in compounding that may present significant safety risksUS Food and Drug Administration
- Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances (Federal Register notice, 30 October 2026)US Department of Health and Human Services
- Bes F, Hofman W, Schuur J, Van Boxtel C. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology. 1992;26(4):193-197Neuropsychobiology (PubMed 1299794)
- Monti JM, Debellis J, Alterwain P, Pellejero T, Monti D. Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs. Int J Clin Pharmacol Res. 1987;7(2):105-110International Journal of Clinical Pharmacology Research (PubMed 3583493)
- Schneider-Helmert D. Efficacy of DSIP to normalize sleep in middle-aged and elderly chronic insomniacs. Eur Neurol. 1986;25(6):448-453European Neurology (PubMed 3792404)
- Schneider-Helmert D. Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia. Eur Neurol. 1987;27(2):120-129European Neurology (PubMed 3622582)
- Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem. 2006;97(2):303-309Journal of Neurochemistry (PubMed 16539679)
- Dick P, Costa C, Fayolle K, Grandjean ME, Khoshbeen A, Tissot R. DSIP in the treatment of withdrawal syndromes from alcohol and opiates. Eur Neurol. 1984;23(5):364-371European Neurology (PubMed 6548969)
- Circular CIR-2026-00000107: Regulations for Handling Peptide Products in Healthcare Facilities, 29 July 2026Dubai Health Authority